Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study
Titel:
Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study
Auteur:
Konecny, Gottfried E Finkler, Neil Garcia, Agustin A Lorusso, Domenica Lee, Paula S Rocconi, Rodney P Fong, Peter C Squires, Matt Mishra, Kaushal Upalawanna, Allison Wang, Yongyu Kristeleit, Rebecca